Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A hormone head start: could estrogen before IVF boost pregnancy chances in PCOS?

NCT ID NCT07727863

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether taking estradiol (a form of estrogen) for about 10 days before starting ovarian stimulation can help women with polycystic ovary syndrome (PCOS) have more synchronized follicle growth and better IVF outcomes. Sixty women with PCOS undergoing ICSI are randomly assigned to receive either estradiol pretreatment or no pretreatment. Researchers will measure follicle size consistency, hormone doses needed, and pregnancy rates to see if this simple step makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
estradiol valerate (a form of estrogen) taken as a pill before starting ovarian stimulation
What this could lead to
If effective, this simple hormone pretreatment could improve egg quality and pregnancy rates in women with PCOS undergoing IVF.
What could go wrong
This is a small, single-center trial, so results may not apply broadly. Estrogen therapy carries risks like blood clots, and the benefit over standard care is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

61 people

The number who actually took part.

Started

Sep 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 37 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PCOS was defined by the presence of at least two of the following: 1. oligo or anovulation, 2. clinical or biochemical hyperandrogenism, and 3. polycystic ovarian morphology on ultrasound (≥12 antral follicles 2-9 mm in diameter and/or ovarian volume \>10 mL). All participants had undergone failed ovulation induction or were candidates for IVF/ICSI due to male factor infertility. Exclusion Criteria: * previous ovarian surgery * endometriosis * known chromosomal abnormalities * untreated thyroid disease * body mass index (BMI) \> 35 kg/m² * basal FSH \>12 IU/L * use of hormonal medications within 3 months prior to the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ivf outcomes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ivf outcomes PCOS GNRH antagonist and GNRH agonist ivf/icsi cycles

Contacts and locations

Locations

  • Cairo University

    Cairo, Cairo Governorate, 12111, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.